Journal of Tongji Medical University

, Volume 14, Issue 4, pp 227–229 | Cite as

Etoposide-based combination chemotherapy in malignant histiocytosis

  • Lin Feng-ru
  • Yao Er-gu


We investigated the responses of patients with malignant histiocytosis (MH) to the treatment of epotoside-based regimen. Of 11 evaluable cases, 9 (81.8%) achieved complete remission and 1 partial remission. 7 complete remission cases (77.7%) received only one therapeutic course. The side effects were mild and welltolerated. We conclude that etoposide-containing regimen is highly effective and can be used as first-line treatment for MH and is worthy of further study.

Key words

etoposide combination chemotherapy malignant histiocytosis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    1992;352–357Google Scholar
  2. 2.
    Tseng A Jr, Coleman C N, Cox R Set al. The treatment of malignant histiocytosis. Blood, 1984; 64: 48PubMedGoogle Scholar
  3. 3.
    Zucker J M, Caillaux J M, Vanel Det al. Malignant histiocytosis in childhood: Clinical study and therapeutic results in 22 cases. Cancer, 1980, 45: 2821PubMedCrossRefGoogle Scholar
  4. 4.
    VP16, 1989, 12, 8Google Scholar
  5. 5.
    Vogelzang N J, Raghavan D, Kennedy B J. VP-16-213 (etopiside): The mandrake root from Essyk-Kul. Am J Med, 1982; 72: 136PubMedCrossRefGoogle Scholar
  6. 6.
    Rowe J M, Chang A Y C, Bennett J M. Aclacinomycin A and etoposide CVP-16-213): An effective regimen in previously treated patients with refractory acute myelogenous leukemia. Blood, 1988, 71: 992PubMedGoogle Scholar
  7. 7.
    Seljelid R, Eskeland T. The biology of macrophages: In general principles and properties. Eur J Haematol, 1993, 51: 267PubMedCrossRefGoogle Scholar

Copyright information

© Springer 1994

Authors and Affiliations

  • Lin Feng-ru
    • 1
  • Yao Er-gu
    • 1
  1. 1.Department of Hematology, Second Affiliated HospitalHebei Medical CollegeShijiazhuang

Personalised recommendations